ABUS vs NOC · P/E 5.4, rev $6.2M vs P/E 17, rev $41.95B
Arbutus Biopharma Corp (ABUS) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported NOC revenue for 2025-12-31 was $41.95B. Net income was $4.18B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the ABUS and NOC stock pages for the full models.
Not investment advice.